137 related articles for article (PubMed ID: 12171567)
21. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
23. The ERBB network: at last, cancer therapy meets systems biology.
Yarden Y; Pines G
Nat Rev Cancer; 2012 Jul; 12(8):553-63. PubMed ID: 22785351
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
25. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
Gaul MD; Guo Y; Affleck K; Cockerill GS; Gilmer TM; Griffin RJ; Guntrip S; Keith BR; Knight WB; Mullin RJ; Murray DM; Rusnak DW; Smith K; Tadepalli S; Wood ER; Lackey K
Bioorg Med Chem Lett; 2003 Feb; 13(4):637-40. PubMed ID: 12639547
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of action of erbB tyrosine kinase inhibitors.
Fry DW
Exp Cell Res; 2003 Mar; 284(1):131-9. PubMed ID: 12648472
[TBL] [Abstract][Full Text] [Related]
27. Dephosphorylation of receptor tyrosine kinases as target of regulation by radiation, oxidants or alkylating agents.
Knebel A; Rahmsdorf HJ; Ullrich A; Herrlich P
EMBO J; 1996 Oct; 15(19):5314-25. PubMed ID: 8895576
[TBL] [Abstract][Full Text] [Related]
28. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling.
Fan QW; Zhang C; Shokat KM; Weiss WA
Curr Biol; 2002 Aug; 12(16):1386-94. PubMed ID: 12194819
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
Fry DW
Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
[TBL] [Abstract][Full Text] [Related]
30. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
[TBL] [Abstract][Full Text] [Related]
32. Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity.
Ahmed MF; Magdy N
Anticancer Agents Med Chem; 2017; 17(6):832-838. PubMed ID: 27671305
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.
Busse D; Yakes FM; Lenferink AE; Arteaga CL
Semin Oncol; 2001 Oct; 28(5 Suppl 16):47-55. PubMed ID: 11706396
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE; Karamanos NK
In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
[TBL] [Abstract][Full Text] [Related]
36. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
37. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
[TBL] [Abstract][Full Text] [Related]
38. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
39. Forthcoming receptor tyrosine kinase inhibitors.
Choong NW; Cohen EE
Expert Opin Ther Targets; 2006 Dec; 10(6):793-7. PubMed ID: 17105367
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
